NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Pumitamig pivotal trials come in pairs
Bristol will test the bispecific in two new lung indications.
Epkinly fails its first confirmatory test
And that could affect the drug's third-line accelerated approval.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
